Targeted protein degradation (TPD) is getting a lot of attention as a promising modality to treat a variety of diseases from ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Discover C4 Therapeutics' groundbreaking patent for BRD9-degrading compounds, targeting disorders like synovial sarcoma. Explore innovative treatments for better outcomes!

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients ...

Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective ...

On his appointment, Steve Fawell, Ph.D. said, “I am delighted to join the Board of Directors at C4 Therapeutics after closely ...

The life-saving use of messenger RNA (mRNA) in COVID-19 vaccines was a public example of the potential of mRNA-based ...